Group items matching

in title, tags, annotations or url

When you visit a hospital, one of the last things that come to mind is worrying about legal aspects and what rights you might have - or lack. But these issues and your understanding of them are more important than ever. Knowing exactly what hospitals can legally and cannot do to you is an essential part of ensuring your protection as a patient when going in for care. In this blog post, we'll break down the legal details behind being treated at a hospital so that you can feel more confident when making healthcare decisions. Let's dive into the legal aspect of visiting a hospital, outline what hospitals can and cannot do to us, discover our rights as patients, and review any other considerations worth keeping in mind! OVERVIEW OF MEDICAL MALPRACTICE LAW AND HOW IT RELATES TO VISITING A HOSPITAL When going to a hospital, concerned patients and their families should be aware of the legal risks posed in medical malpractice cases. These potential issues can have life-altering consequences if misdiagnoses, wrong medication administration, or improper treatment occurs. Now, whether you seek damages for your injuries at Staten Island University Hospital or in a different hospital in your hometown, it is important for visitors to understand that the law has set forth regulations regarding acceptable standards of care expected by our nation's hospitals. Those regulations can include procedures of qualified professionals that protect patients from financial exploitation and physical or emotional distress caused by medical negligence. Understanding how this information applies to you will help you protect yourself legally if your rights are violated while visiting a hospital.

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

Esperion Therapeutics' non-statin therapy "bempedoic acid" has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company. As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData. According to GlobalData's Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025. Neha Myneni, Pharma Analyst at GlobalData, comments: "Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space." Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

The PSNC on Friday said it has warned the DHSC about the "very serious impact" of the limited supply of certain antibiotics on pharmacies who are "having to chase stock, purchase without sight of any concession prices, and cope with increasing patient questions and abuse." With higher than usual number of cases of scarlet fever, caused by invasive Group A Streptococci (iGAS) infections, being reported in children across the country, supplies of antibiotics for Group A Strep treatment have seen a surge in demand, leading to limited supply at certain wholesalers and pharmacies. PSNC has urged the DHSC to adopt measures that could help to manage the current crisis, such as allowing pharmacists more freedom to change strengths or formulations without prescriber approval, outside of Serious Shortage Protocols. It has also raised concerns on the significant rise in wholesale prices of many oral antibiotics as a result of the surge in demand and the ongoing supply disruptions. PSNC also said they have received reports of some suppliers putting up their prices for any oral antibiotics they do have in stock.

There are many reasons why people might need help with their dental problems. Maybe they don't have insurance, or maybe they just don't have the money to go to a dentist. In these cases, the pharmacy can be a great option. Pharmacists can provide a variety of services that can help people with their dental problems, including over-the-counter medications and advice on how to take care of teeth and gums. In this blog post, we will discuss some of the ways that pharmacies can help you take care of your teeth! So, whether you have a toothache, cavities, or bad breath, a pharmacy can be a great place to turn. 1) OVER-COUNTER MEDICATIONS One of the most common services that pharmacies provide is the sale of over-the-counter medications. These medications are designed to be taken for short periods of time and can help with a variety of dental problems. For example, if you have a toothache, you can buy an antiseptic rinse or analgesic gel that can help relieve the pain. If you have bad breath, you can buy mouthwash or breath fresheners that will help mask the odor. And if you have cavities, you can purchase fluoride rinses or gels that can help with decay prevention. If you are worried about the cost of dentists, these medications can be a great way to get the relief you need without breaking the bank. However, it doesn't mean that you should neglect regular dental visits! 2) PROVIDE YOU WITH EDUCATION Another way pharmacy can help you with your dental problems is through advice and education. Pharmacists are trained to provide general information on oral hygiene and health and can help you make educated decisions about which products to buy. They can also provide recommendations on how often you should brush and floss your teeth, as well as advice on diet and lifestyle choices that can help prevent dental problems. In addition, some pharmacies may even have an oral health specialist on staff who can answer any questions you might have about your teeth or gums

With higher than usual number of cases of scarlet fever, caused by invasive Group A streptococci (iGAS) infections being reported in children across the country, Chief Pharmaceutical Officer for England David Webb has assured pharmacies of sufficient supply of antibiotics. In a letter, shared by the PDA, Webb also urged the pharmacies to order antibiotic stocks sensibly. "Local pharmacy teams may be experiencing a temporary interruption of supply of some relevant antibiotics due to increased demand. On a national level, sufficient stock exists for the NHS," he said. He said NHS is working closely with the Department of Health and Social Care (DHSC) and has taken actions to help ensure medicines continue to be available. He explained that the supplies of antibiotics for the treatment of Group A Strep, particularly phenoxymethylpenicillin presentations, have seen a surge in demand, leading to potential constraints at certain wholesalers and pharmacies,

he Healthcare Distribution Association (HDA) and the Pharmaceutical Services Negotiation Committee (PSNC) have urged the NHS England and the Department of Health and Social Care (DHSC) to issue urgent communications requesting that all those involved in medicines supply do not hoard, stockpile or over-prescribe Strep A antibiotics. In a statement HDA said that the sudden spike in demand for antibiotics used for the treatment of Strep A has meant that there is not enough of these medicines in the supply chain currently to meet this increased demand. As a result, wholesalers are working extremely hard with manufacturers to increase the supply of antibiotics. It added: "As regards pricing, the prices charged to pharmacies by HDA wholesale distributors will directly reflect the increase in prices wholesalers are having to pay for these medicines from manufacturers at the moment, in order to be able to continue supplying these medicines to pharmacies. This will be the case until supply and demand are more in sync."

The UK Health Security Agency (UKHSA) has suggested that the Live Attenuated Influenza Vaccine (LAIV) vaccine that offers protection to children against flu may also help reduce the rate of group A strep infections. LAIV is a nasal spray offered each season to most children aged 2 and 3 years old, and to school-aged children, to help protect against flu. The new study looked back at data from 2013 to 2017, comparing rates of group A strep (GAS) infections in pilot areas and comparing them to other areas where the vaccine was not being offered as widely. It was found that incidence of GAS was lower in pilot areas where the LAIV vaccine was being offered to all primary school children, compared to areas where it was being incrementally rolled out. The study revealed, in 2 to 4 year olds, rates of GAS were 73.5 per 100,000 children in pilot areas, compared to 93 per 100,000 children in non-pilot areas. In 5 to 10 year olds, rates of GAS were 50.3 per 100,000 children in pilot areas, compared to 57.8 per 100,000 in non-pilot areas.

Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies has said pharmacists have been "struggling to obtain the very basic, most common cold and flu medicine." She told the PA news agency that the shortage wasn't around "just the branded medicines" but "also simple things like throat lozenges, cough mixtures or pain killers - particularly the ones that are soluble." Stating that the sector was finding it very difficult these shortages she said "those people who are in charge of supporting us with it are denying it." "The demand has been high because this season we've seen higher cases of colds and flu and people are obviously trying very hard to look after themselves and making sure that they use the relevant products to manage the symptoms.

A survey of over six thousands pharmacies has revealed that the community pharmacy sector is buckling under growing cost and capacity pressures. The survey conducted by the Pharmaceutical Services Negotiating Committee, which also involved two thousand community pharmacy confirms, rising costs, patient demand and medicine supply issues continue to grip the sector. PSNC's 2023 Pharmacy Pressures Survey, run as a follow up to the 2022 pressures survey, provides clear comparative data showing the worsening situation across the sector. Govt must act now The result of the survey indeed paints a bleak picture for community pharmacies and it is clear that without urgent action from government and the NHS this will only get worse: more community pharmacies will either be forced to reduce the number of services they provide or, in the worst-case scenario, will be left with no option but to close their doors for good. The PSNC has urged the government to act now "to save our pharmacies, before it is too late for patients, the public, and the rest of the NHS". "This year's survey clearly shows that community pharmacies are buckling under growing cost and capacity pressures," said PSNC Chief Executive Janet Morrison.

At the European Conference of Clinical Microbiology & Infectious Diseases (ECCMID) this year in Copenhagen, Denmark, data on a test that may detect HIV, hepatitis B, and hepatitis C from a single drop of blood are being presented. Hepatitis B or C claim the lives of over a million people each year. Every year, 1.5 million individuals contract HIV, and 650,000 people pass away from HIV-related causes. The World Health Organisation has made the elimination of all three viruses by 2030 one of its global health strategies but new tests are necessary if case numbers are to be reduced. The most common test for hepatitis B, hepatitis C and HIV involves taking a blood sample from a vein using a needle. While this method works extremely well, there is a potentially large reservoir of the three conditions in places where this method is not suitable. This could be prisons, drug rehabilitation centres and homeless shelters, where the taking of venous blood samples isn't always suitable or countries in which the shipping and refrigerated storage of blood samples can be challenging. Alternatives include dried blood spot tests, in which a single spot of blood is tested for nucleic acid from the three viruses.

The Association of Independent Multiple Pharmacies (AIMp) has changed its name to the Independent Pharmacies Association (IPA). AIMp, now IPA, stated that rebranding was prompted by the demand from independent community pharmacists for an association that properly represents their interests. The membership of the Independent Pharmacies Association will not be restricted to pharmacy owners with multiple branches, as was the case with AIMp, but will be open to all independents, it announced today (Tuesday). It believes that the switch will "provide a clearer identity and afford a strong voice to the thousands of independent pharmacies in England and Wales." Furthermore, the IPA noted that it will not primarily function as an insurance organisation with membership attached, but it will be "fighting for and representing its members across all fronts."

It isn't the hardest thing to find the right physiotherapist to treat you, but like many other professions, especially in health, physiotherapy has a number of different areas of expertise that are governed by strict and high standards of service. Physiotherapists have to be well educated and officially registered in order to practice. Identifying which therapist is able to provide the treatment for your specific needs and requires more than just picking up a phone book, or selecting the first site that pops up on google. Here's a list of what to look for when selecting a therapist as well as when to look for one. What to Look for Check their qualifications As is the case with any healthcare practitioner, it is important that your physiotherapist is fully qualified and accredited. It is required by law that they complete a degree at an approved educational institution, and are registered with the Physiotherapy Board. The board is responsible for keeping professional standards up to where they need to be, and for making sure that the Code of Practice is upheld.

Sinus infection lasting for months or years is called chronic sinusitis.Majority of the cases of acute sinusitis occurs due to failure of the acute infection to resolve.

https://misoprostolhotline.com/dosis-cytotec-1-bulan/ misoprostolhotline : call 08574 0559 466. Jual Obat Cytotec di Jakarta Bandung.Jogjakarta

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio. Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases. Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen. The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas. Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise. Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen, providing a vital treatment option for patients.

AMS 2024: Internal Medicine A Review And Update-Rheumatology, Endocrinology, And Cardiology is organized by American Medical Seminars, Inc. and will be held from May 20 - 23, 2024. Clinical approach to rheumatology (Wasko) Diagnostic testing in rheumatic diseases (Wasko) Thyroid Case Studies (Winters, S) Polycystic Ovary Syndrome (Winters, S) Hypo and Hypercalcemia (Winters, S)

The government's 200 million dental recovery plan has come under fierce criticism from the opposition party after health minister Dame Andrea Leadsom admitted that there is a "high likelihood" that it will not deliver 2.5 million dental appointments. Published last month, the plan is aimed at ensuring easier and faster access to NHS dental care across England, with up to 1.5 million extra treatments expected to be delivered over the next 12 months. Various new measures were set out to attract new dentists, including increasing dental training places by up to 40 per cent by 2032, as part of the NHS Long Term Workforce Plan. On Tuesday, Leadsom told MPs on the Health and Social Care Committee that the figure was based on NHS modelling of a "complicated set of factors" and there is "quite a high likelihood of not being reliable as is the case with all modelling." Preeti Kaur Gill MP, shadow minister for primary care and public health, expressed shock over the admission by the public health minister that there is uncertainty regarding the plan's ability to deliver on its promises, which she said: "shows the Conservatives are out of ideas and out of time."

The Competition and Markets Authority (CMA) has revoked its initial enforcement order imposed on Pharmacy2U Limited (Pharmacy2U) concerning the acquisition of Metabolic Healthcare Ltd (Lloyds Direct). In the revocation order issued on February 12, the regulator said its decision was "based on the evidence it has received in its assessment of the Merger to date." The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Pharmacy2U, P2U Holdings Limited, G Square Capital II L.P., G Square Healthcare Private Equity LLP (collectively, the Acquirer Group) and Lloyds Direct on 28 November 2023. It announced that it was considering "whether it is or may be the case that a relevant merger situation has been created and whether the creation of that situation has resulted or may be expected to result in a substantial lessening of competition in any market or markets in the United Kingdom (UK)."

Britain's antitrust regulator, the Competition and Markets Authority (CMA) on Wednesday announced that it is investigating the acquisition of LloydsDirect by Pharmacy2U last year, and has launched its first phase of the merger inquiry. The completed deal between two of the UK's foremost online pharmacies was announced in a joint statement issued on 9 October, confirming that they would operate as Pharmacy2U. Commenting on the purchase, Kevin Heath, CEO of Pharmacy2U, then said: "Combining the best of both of our businesses, we can provide patients with greater access and convenience." The regulator is considering "whether it is or may be the case that this merger has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services."